Dr. Luis BERMUDEZ is a senior scientist at Micalis institute in the team “Interactions of commensal and probiotic microorganisms with the host” and in charge of scientific group: Probiotics and Therapies based on Microbiota (Acronym: Protect). His research focuses primarily on the therapeutic and innovative uses of recombinant, naturally occurring and genetically modified recombinant lactic acid bacteria (LAB) and probiotics for modulating the host immune response at mucosal surfaces. He is among the world’s early leaders in the field of using these live vectors for the development of novel mucosal vaccines. He is an expert in microbiology, molecular biology, vaccinology and animal models. He has also succeeded in obtaining grants from the French Ministry of Research, the French Association for Cancer Research (ARC) and the European project FP6: Pathogen Combat, and has been recognized with several awards. He has published more than 140 articles in international peer-reviewed journals and holds 10 patents. He is also co-founder of the biotech start-up microXpace.
luis-bermudez
